| Date | Title | Description |
| 22.01.2026 | Exciva Secures €51 Million Series B: Alzheimer's Agitation Therapy Advances to Phase 2 | Exciva closed a €51 million Series B funding round. This financing fuels Deraphan, its Alzheimer's agitation therapy, into crucial Phase 2 trials. EQT Life Sciences and Gimv spearheaded the investment. The global study addresses a pressing ... |
| 20.01.2026 | Exciva: €51 Million Series B Closed To Advance Alzheimer’s Agitation Therapy Into Phase 2 | EQT Life Sciences announced it co-led a €51 million Series B financing in Exciva, a clinical-stage biopharmaceutical company developing treatments for behavioral symptoms associated with Alzheimer’s disease, with proceeds earmarked to move ... |
| 12.01.2026 | Haemonetics Acquires Vivasure Medical | Vivasure Medical, a Galway, Ireland-based company advancing novel fully absorbable technology for percutaneous vessel closure, has been acquired by Haemonetics Corporation (NYSE: HAE), a Natick, Massachusetts based global provider of blood ... |
| 09.01.2026 | Galways's Vivasure Medical acquired for up to €185m | Vivasure Medical, the Galway-based medical device company, has been acquired by the NYSE-listed Haemonetics Corporation in a deal worth up to €185m if certain conditions are met.
Vivasure develops advanced polymer implants and delivery syst... |
| 20.02.2024 | Health | Inside the plan to diagnose Alzheimer’s in people with no memory problems — and who stands to benefit | Melody Petersen | Los Angeles Times (TNS)
In a darkened Amsterdam conference hall this summer, a panel of industry and academic scientists took the stage to announce a plan to radically expand the definition of Alzheimer’s disease to includ... |
| 16.10.2023 | AstronauTx, developing treatments for Alzheimer's, raises $59M Series A | The startup works in partnership with UCL and is backed by Novartis and UK gov't funds
In the United States alone, about 10.7% of people age 65 and older are living with Alzheimer's – the most common form of dementia. That number is project... |
| 03.03.2023 | Oculis goes public on Nasdaq | |
| 18.10.2022 | Oculis to go public via SPAC | |
| 11.02.2022 | Amsterdam-based Life Science Partners closes €1B funding for its flagship ‘LSP 7’ fund | Life Science Partners (LSP), an Amsterdam-based investment firm that provides finance for life sciences and health care companies, announced that it has raised over €1B for its flagship fund LSP 7.
With the LSP 7 fund, the Dutch firm plans ... |
| 11.02.2022 | As it prepares to join EQT, Life Science Partners surpasses €1B investment mark | Just a few months ago, the European investment firm Life Science Partners announced that it would be bought out by the private investment group EQT, a VC firm with more than $2.5 billion under management. Friday, it revealed that it has sur... |
| 09.02.2022 | Neurovascular company Perfuze raises €22.5M ($25M) Series A for a new stroke treament | Galway, Ireland, February 9th, 2022 –Perfuze, a medical device company developing next-generation catheter-based aspiration technology to treat large vessel occlusion acute ischemic stroke, has closed a €22.5 million Series A investment rou... |
| 11.11.2021 | International: EQT strengthens position in healthcare investments by joining forces with LSP | 11/11/2021
Press release
INTERNATIONAL: EQT STRENGTHENS POSITION IN HEALTHCARE INVESTMENTS BY JOINING FORCES WITH LSP.
EQT AB (publ) today announces the signing of an agreement (the “Transaction”) to acquire LSP (“Life Sciences Partners”... |
| 11.11.2021 | What does the recent third quarter drop in late-stage startup valuations mean? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
With decacorns born left and right nowadays, it’s hard to believe that valuations are pulling bac... |
| 11.11.2021 | What does the recent third quarter drop in late-stage startup valuations mean? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
With decacorns born left and right nowadays, it’s hard to believe that valuations are pulling bac... |
| 10.11.2021 | EQT strengthens position in healthcare investments by joining forces with LSP | EQT AB (publ) today announces the signing of an agreement (the "Transaction") to acquire LSP ("Life Sciences Partners" or the "Company"), a leading European life sciences venture capital firm with approximately... |
| 10.11.2021 | EQT strengthens position in healthcare investments by joining forces with LSP | EQT strengthens position in healthcare investments by joining forces with LSP Wed, Nov 10, 2021 08:31 CET
EQT AB (publ) today announces the signing of an agreement (the “Transaction”) to acquire LSP (“Life Sciences Partners” or the “Company... |
| 10.08.2021 | Visus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage Partners | Proceeds will support clinical and commercial efforts for lead asset BRIMOCHOL™ under investigation for presbyopia as well as new research and development activities in the Company’s drug development pipeline
Strengthens its Board of Direct... |
| 23.04.2021 | Fresh capital for ONWARD to tackle spinal code injuries | ONWARD’s ARC therapy can be delivered by an implantable system called ARC-IM and an external system called ARC-EX. Both platforms are designed to deliver targeted, programmed stimulation of the spinal cord to restore movement, independence,... |
| 23.04.2021 | Fresh capital for ONWARD to tackle spinal cord injuries | |
| 14.01.2021 | As venture funding in oncology flourishes, neuro has seen shallower pockets. A European investor wants to change that | Big Pharma has retreated from neuroscience over the past several years, abandoning or trimming back programs after facing setbacks in difficult-to-treat brain disorders. And now, René Kuijten says dementia opportuni... |
| 09.07.2020 | VarmX raises €32M in Series B financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants | 08/07/2020
Press release
VARMX RAISES €32 MILLION IN SERIES B FINANCING TO DEVELOP INNOVATIVE REVERSAL AGENT FOR THE TREATMENT AND PREVENTION OF SEVERE BLEEDING IN PATIENTS ON ORAL ANTICOAGULANTS.
• Financing co-led by Ysios Capital and ... |
| 08.07.2020 | Ysios Capital lidera una inversión de €32M en VarmX | 08/08/2020
Nota de prensa
YSIOS LIDERA UNA INVERSIÓN DE €32 MILLONES EN VARMX.
– VarmX (Leiden,Países Bajos), está desarrollando un fármaco innovador para el tratamiento y prevención de hemorragias graves en pacientes tratados con antico... |
| 11.03.2020 | Amsterdam-based investment firm LSP secures €530M in largest European life sciences investment fund | LSP (Life Sciences Partners), the leading life sciences investor in Europe, has recently announced that it has held its final close of LSP 6 at the $600 million (approx €530 million) hard cap. To date, this has been the largest fund ever ra... |
| 10.03.2020 | Bristol Myers powers LSP to record-breaking European VC fund | LSP has raised a $600 million (€529 million) fund to invest in European life science companies. The investment vehicle, which LSP claims is the largest of its type in Europe, is bigger than the VC shop’s three previous life science funds co... |
| 10.03.2020 | LSP Closes European Life Sciences Fund, at $600M | LSP, a life sciences investor in Europe, has held its final close of LSP 6 at the $600m hard cap.
LSP 6 received capital from a diverse investor base including pension funds, insurance companies, wealth managers, government funds and family... |
| 10.03.2020 | Bristol Myers powers LSP to record-breaking European VC fund | LSP has raised a $600 million (€529 million) fund to invest in European life science companies. The investment vehicle, which LSP claims is the largest of its type in Europe, is bigger than the VC shop’s three previous life science funds co... |
| 19.02.2020 | Endotronix Enrolls First Patients in PROACTIVE-HF Pivotal Trial | LISLE, Ill. /PRNewswire/ — Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), today announced the enrollment of the first two patients in the PROACTIVE-HF pivotal ... |
| 11.12.2019 | These 6 investors in Amsterdam have contributed to making the city a leading tech startup hub in 2019 | It is widely known that Amsterdam is home for many fast-growing startups and a slew of unicorns such as Takeaway.com, WeTransfer, Booking.com, and many others. Notably, all these are global players in their own fields. Also, Amsterdam has m... |
| 01.10.2019 | Endotronix Closes Expanded Series D Financing Round of $70 Million for Heart Failure Solution | LISLE, IL – Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure (HF), today announced the expansion of its Series D financing round, bringing the total for the round to $70 million. The ... |
| 06.09.2019 | Xeltis’ closes €10.5 million Series D financing | |
| 15.02.2019 | Axovant spin-off launched in Basel with an initial funding of over CHF100m | |
| 07.12.2018 | Lumeon secures $28m in funding to accelerate growth in the US market | Lumeon, the leader in Care Pathway Management (CPM), has announced the closure of a $28m investment led by LSP, one of Europe’s largest healthcare investment firms. The funding includes venture capital from MTIP and participation from curre... |
| 07.12.2018 | Lumeon secures $28m in funding to accelerate growth in the US market | Lumeon secures $28m in funding to accelerate growth in the US market
07-12-2018
Lumeon, the leader in Care Pathway Management (CPM), has announced the closure of a $28m investment led by LSP, one of Europe’s largest healthcare investment fi... |
| 14.09.2018 | Endotronix Raises $45 Million in Series D Financing for the Treatment of Heart Failure | Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure, today announced the close of a Series D financing round totaling $45 million. The round was led by LSP, investing from its LSP Health... |
| 14.09.2018 | MedTech Startup Endotronix Lands $45M for Heart Failure System | Endotronix, Inc., a digital health, MedTech company dedicated to advancing the treatment of heart failure, today announced it has raised $45 million in Series D funding led by LSP, investing from its LSP Health Economics Fund 2. The round a... |
| 26.04.2018 | Cardiac Dimensions Announces $39 Million Series B Financing for Innovative Device to Treat Patients With Heart Failure | KIRKLAND, Wash.–(BUSINESS WIRE)– Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for patients with heart failure, today announced the company has closed a $39 million Series B financing. The roun... |
| 12.12.2017 | LSP closes $330M medtech fund, plots 15 investments | LSP has raised $330 million for its second medical technology fund. The big jump in size over the first fund tees up LSP to place bets on 15 companies with close-to-market devices, diagnostics and digital health tools.
Amsterdam-based LSP i... |
| 12.12.2017 | LSP closes $330M medtech fund, plots 15 investments | LSP has raised $330 million for its second medical technology fund. The big jump in size over the first fund tees up LSP to place bets on 15 companies with close-to-market devices, diagnostics and digital health tools.
Sponsored by Agilent ... |
| 15.11.2017 | Xeltis mit Rekordfinanzierung | |
| 15.11.2017 | Xeltis Closes €45 Million in Series C Financing | |
| 06.11.2017 | Versant Ventures Joins 42M Euros Series B for NousCom | NousCom, an oncology company developing neoantigen based cancer vaccines based on its Exovax platform, today announced the completion of a €42 million Series B financing. The round involved a syndicate of leading transatlantic life sciences... |
| 06.11.2017 | 5AM Ventures Joins 42M Euros Series B for NousCom | NousCom, an oncology company developing neoantigen based cancer vaccines based on its Exovax platform, today announced the completion of a €42 million Series B financing. The round involved a syndicate of leading transatlantic life sciences... |
| 26.07.2017 | New nonmetal cervical disc set to reduce radiation exposure for patients after surgery | Simplify enters a crowded replacement disc market.
However, the company is banking that its nonmetal discs will provide a significant competitive advantage. Metal discs create artifacts that can reduce MRI image quality, forcing clinicians ... |
| 30.08.2016 | Mint Solutions Raises healthy €5M Series B investment to Revolutionize Medication Safety | Dutch-Icelandic medical startup Mint Solutions Holding BV has found the right medicine to cure its funding woes in the form of a € 5 million Series B equity funding round investment . The healthy donors are led by the Brabant Development Ag... |
| 25.08.2016 | Mint Solutions Raises $5.6M Series B from Life Sciences Partners | Mint Solutions Holding BV, a private Dutch company developing and marketing the revolutionary medication safety system MedEye, has raised € 5 million in a Series B equity funding round led by the Brabant Development Agency (BOM Capital) and... |
| 16.08.2016 | Rotation Medical Raises $12M Series B from Life Sciences Partners | Rotation Medical Inc., a medical device company focused on developing new technologies to treat rotator cuff disease, today announced that it completed a $12 million Series B extension financing.
The existing investors – New Enterprise Asso... |
| 16.08.2016 | Rotation Medical Raises $12M Series B from Life Sciences Partners | Rotation Medical Inc., a medical device company focused on developing new technologies to treat rotator cuff disease, today announced that it completed a $12 million Series B extension financing.
The existing investors – New Enterprise Asso... |
| 02.06.2016 | Life Sciences Investment Firm Life Sciences Partners Closes Fund, at $280M | European life sciences investment firm Life Sciences Partners (LSP) closed its new life sciences fund, at $280m.
LSP 5, which surpassed its $170m target, primarily focuses on Europe, looking to invest in around 20 companies across the areas... |
| 17.05.2016 | New company of former Okairos founders bags €12 million | |
| 19.04.2016 | G-Therapeutics raises EUR 36 million | |
| 17.12.2015 | Xeltis acquires additional €3M in series B financing | |
| 24.11.2015 | Bristol-Myers Squibb Company Invests in Life Sciences Partners’ Fund | European healthcare investment firm Life Sciences Partners is teaming up with Bristol-Myers Squibb Company.
The collaboration sees Bristol-Myers Squibb making an investment in LSP 5, the latest LSP fund with a representative joining the LSP... |
| 16.11.2015 | KUROS announces second closing of a CHF 20 million financing round | |
| 23.10.2015 | Sequana Medical AG raises CHF 9 million | |
| 14.10.2015 | Luxendo Closes €6M Series A Financing | Luxendo, a startup launched by the European Molecular Biology Laboratory (EMBL) and its technology transfer arm EMBLEM Technology Transfer (EMBLEM) in Heidelberg, Germany, closed a €6M Series A financing.
The round was co-led by EMBL Ventur... |
| 19.08.2015 | Kuros announces closing of a CHF 15m financing round | |
| 02.12.2014 | Xeltis closes CHF 32 million Series B financing | |
| 08.07.2014 | Mint Solutions Secures €4.425M in Series A Financing | Mint Solutions, an Amsterdam, the Netherlands-based developer of a platform which helps patients get the right medication at the right time, secured €4.425m in Series A financing.
Backers included Life Sciences Partners and Seventure Partne... |
| 28.04.2014 | Sequana Medical Raises CHF23M in Series C Financing | Sequana Medical AG, a Zurich, Switzerland-based medical device company with innovative fluid management technologies, has raised CHF23m ($26.2m) in a Series C financing.
The round was led by LSP (Life Science Partners), and co-led by NeoMed... |
| 28.04.2014 | Sequana Medical AG raises CHF 23 million in a Series C financing led by LSP | |
| 14.03.2014 | Life Sciences Partners Closes Fund at €112M | Life Sciences Partners, a European life sciences investor, held the final closing of its latest fund at €112m (approximately $155m).
LPs include Dutch, German and French health insurance companies, family offices and asset managers.
Led by ... |
| 29.05.2013 | GSK acquires Okairos AG for EUR 250 mio | |
| 28.09.2012 | IlluminOss Medical Secures $28M in Series C Venture Capital Financing | IlluminOss Medical, Inc., a East Providence, RI-based developer of photodynamic orthopedic implants, has secured $28m in Series C venture capital financing.
The round was co-led by Tekla Capital Management and Life Sciences Partners, with p... |
| 11.11.2009 | Cellerix levanta €27M en el 1º cierre de la 2ª ronda liderada por Ysios, LSP y Ventech | 11/11/ 2009
Nota de prensa
CELLERIX LEVANTA €27 MILLONES EN EL PRIMER CIERRE DE LA 2ª RONDA LIDERADA POR YSIOS, LSP Y VENTECH.
Cellerix, empresa biofarmacéutica líder en la producción y desarrollo de medicamentos innovadores basados en e... |
| - | New nonmetal cervical disc set to reduce radiation exposure for patients after surgery | Australian company Simplify Medical recently raised $21 million in a Series B round to support two pivotal clinical trials and commercialize its polymer/ceramic cervical device in Europe. The investment was led by Life Sciences Partners and... |
| - | Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease | August 25, 2021 |
| - | Immunic successfully closes 17.5 million Euro Series A financing round | Immunic AG (Immunic), a recently formed private start-up biotech company in Planegg-Martinsried near Munich, Germany, today announced that it has closed its Series A financing round totaling EUR 17.5 million of preferred stock financing. Th... |
| - | Belgian startup offering smart lamp for older adults raises €13 million to redefine health care | The aging population continues to grow at a rapid pace. Currently, one-fifth of the European population is already older than 65. By 2040, it is estimated to reach no less than a quarter. With an acute shortage of healthcare personnel, the ... |
| - | French biotech DNA Script raises $200 million, pushes forward with desktop DNA printer | Parisian life sciences technology company DNA Script has raised $200 million in a Series C funding round. The company has developed an alternative to traditional DNA synthesis, a proprietary mechanism it calls Enzymatic DNA Synthesis. This ... |
